

Yorkshire & Humber Neonatal Network (South) Clinical Guideline

Title: Pulmonary Haemorrhage (neonatal)

Author: Claire Blythe (adapted from Elizabeth Pilling, P Adiotomre and R Kacheroo)

Date written: October 2017

Review date: March 2021

This clinical guideline has been developed to ensure appropriate evidence based standards of care throughout the Yorkshire & Humber Neonatal ODN (South). The appropriate use and interpretation of this guideline in providing clinical care remains the responsibility of the individual clinician. If there is any doubt discuss with a senior colleague.

Best practice recommendations represent widely used evidence-based practice and high quality standards that all Neonatal Units across the Network should implement. Subsequent suggested recommendations may be put into practice in local units. However, alternative appropriate local guidelines may also exist.

A. Summary page

1. Aim of guideline

The aim of this guideline is to provide evidence based management of significant pulmonary haemorrhage in infants.

2. Minimum standards where appropriate

As a minimum, neonatal units should have a guideline for the management of pulmonary haemorrhage

3. Summary

Summary of management:

Minor haemorrhage

- Close monitoring
- Avoidance of suctioning
- Check full blood count/clotting screen- correct as appropriate any clotting abnormalities (see Y&H ODN (South) guideline)

Major haemorrhage

Immediate management:

Manage airway, breathing and circulation

- Intubate and avoid removing ET tube
- Avoid suction
- Increase pressures and inspiratory time
- In shocked infants, provide circulatory support with blood product replacement

Subsequent management

- Monitor blood gases
- in hypoxic infants, consider a dose of surfactant (200mg/kg)
- Manage hypotension (as per Y&H ODN (South) guideline)
- Correct haematological parameters (see Y&H ODN (South) guideline)
- Treat for sepsis
- Closely monitor and manage fluid balance- consider fluid restriction and diuretics
- In infants with massive haemorrhage, consider endotracheal adrenaline

B. Full guideline

1. Background

Pulmonary haemorrhage is a relatively common but serious complication seen predominantly in preterm infants.

There are many definitions, however a working definition would be the appearance of fresh blood in the ET tube/ trachea accompanied by a clinical deterioration.

The incidence of pulmonary haemorrhage is 1-12 per 1000 live births. The median age at onset is 46 hours for the preterm baby born at 34 weeks and below. However, for the near term or full term baby born after 34 weeks of gestation the median age at onset is 6 hours¹.

The 18 month outcomes of infants following a serious pulmonary haemorrhage were significantly worse (incidence of death or neurosensory impairment of 75% compared to 43% in matched infants without haemorrhage, OR 3.36).²

2. Aim

The aim of this guideline is to provide evidence based management of significant pulmonary haemorrhage in infants.

3. Areas outside remit if applicable

Management of insignificant pulmonary haemorrhage

4. Core guideline

4.1 Aetiology

The exact cause remains unknown. The lung effluent of infants with pulmonary haemorrhage has a low haematocrit and small molecular weight proteins, leading to the conclusion that in most cases, it is due to haemorrhagic oedema rather than whole blood.

The pathogenesis of PH is therefore considered to be alveolar over distension with high pulmonary capillary pressure causing epithelial breaks and leakage into the air spaces. This is thought to be caused by overdistention of the alveoli by mechanical ventilation and increased pulmonary capillary pressure due to a patent ductus arteriosus. There is circumstantial evidence to support this, with the risk factors associated with PH including ventilation, prematurity, PDA³.

4.2 Risk factors^{1,4}

Risk factors for development of pulmonary haemorrhage are:

For preterm infants:

- Preterm birth
- Lack of antenatal steroids
- Need for positive pressure ventilation
- Surfactant therapy
- Patent ductus arteriosus
- Thrombocytopenia ($<100 \times 10^6$)

For term infants

- Hypoxia
 - In utero (i.e. infants with growth restriction)
 - Intrapartum (i.e. infants with hypoxic ischemic encephalopathy)
 - Post-partum (e.g. infants with meconium aspiration syndrome, difficult intubation leading to hypoxia)
- Delivery room resuscitation with positive pressure ventilation
- Hypotension

4.3 Prevention

Antenatal

Use of antenatal steroids in women at risk of preterm birth

Respiratory

Avoidance of hypoxia (especially in term infants who require resuscitation)
Avoidance of “unnecessary” doses of surfactant (see Y&H Neonatal ODN (South) RDS guideline)

Cardiovascular

Management of hypotension (see Y&H Neonatal ODN (South) hypotension guideline)

Management of PDA (see Y&H Neonatal ODN (South) guideline)

Avoidance of fluid overload (as this increases risk of PDA)

4.4 Diagnosis

There is considerable debate in the literature about the diagnostic criteria of pulmonary haemorrhage. Many infants have blood streaked endotracheal aspirates, however these frequently represent local trauma rather than significant haemorrhage. In the TIPPS⁵ trial 15.6% of infants had some blood aspirated from the endotracheal tube, however 10.2% of infants had “serious” pulmonary haemorrhage, defined as requiring increase in ventilator support, oxygen requirement or blood product replacement.

Table 1 describes the clinical differences and actions:

Diagnosis	Significant pulmonary haemorrhage	Minor pulmonary haemorrhage
Suction findings	Copious Amounts of fresh blood	Minimal staining of ET secretions with fresh or old blood
Clinical observations	Tachycardia, ↓BP, Pallor Acute deterioration in ventilation	No signs of acute deterioration
Management	See below	Most likely diagnosis - traumatic bleeding Suggest minimal suctioning and watch for clinical deterioration

A chest x-ray taken at the time will show patchy changes (the blood), signs consistent with heart failure. If there is a massive haemorrhage, complete “white out” maybe seen do to obstruction of the endotracheal tube with blood clots.

4.5 Treatment

4.5.1 Minor pulmonary haemorrhage

This may be a precursor to major haemorrhage, therefore the infant should be closely monitored and wherever possible suction and re-intubation avoided.

4.5.2 Significant pulmonary haemorrhage

Infants with massive PH can be acutely unwell with hypovolaemic shock.

Initial Management

Assess as ABC:

- Airway

If the infant is not intubated, this will be necessary. However, this can be difficult due to haemorrhage. The member of staff most experienced at intubation should perform this procedure in this situation. Note end tidal CO₂ monitoring may be unhelpful in this situation as it may be falsely negative.

In infants who are intubated, avoid removing the endotracheal tube, as replacing it can be extremely difficult. If the tube is completely blocked with blood, suction may be necessary. However wherever possible, this should be avoided as it can precipitate further haemorrhage.

- Breathing

There may be significant hypoxia during haemorrhage. The mean airway pressure should be increased. This can be achieved by increasing the PEEP (e.g. 6-8, inspiratory time (e.g. 0.4-0.5), PIP (or tidal volume if on VG) in steps. This helps by redistributing the lung fluid into the interstitial spaces and improving ventilation. High frequency oscillation can also be used in this situation where available⁶.

- Circulation

Infants with significant haemorrhage are often bradycardic and hypotensive. Blood replacement may be required urgently depending on the degree of haemorrhage, however note that the cause of PH is usually pulmonary oedema, therefore avoidance of further fluid overload is important. Wherever possible, "useful" fluid replacement should be given e.g. blood products, rather than saline.

Hypotension should be managed as per Y&H Neonatal ODN South guideline with the early use of inotropes.

Further therapy

Once the infant is acutely stabilised the following therapies can be considered.

- Respiratory

Surfactant

There are no randomised controlled trials looking at the use of surfactant in PH, however there are a number of observational/ retrospective studies. A dose of 200mg/kg is used, once the infant has been stabilized if they still have a significant oxygen requirement. This is thought to act by replacing the surfactant inactivated by haemorrhage⁷.

Blood gases

Close monitoring of blood gases is necessary following significant pulmonary haemorrhage. Correction of acidosis may be needed, but this should be done once the other causes have been treated (e.g. hypotension). Note that bicarbonate boluses may contribute to further haemorrhage by increasing volume overload.

If ventilation is difficult, and the baby is unsettled, sedation and muscle relaxation may be required for a short period of time to allow for physiological stability to be achieved.

- Cardiovascular/Haematology

Urgent samples should be taken for coagulation studies and full blood count. Correction may be required (see Y&H Neonatal ODN South guidelines). Again, caution is needed with excessive fluid correction.

- Fluids

Once the infant is cardiovascularly stable, fluid restriction and diuretics may be indicated to reduce the risk of fluid overload.

- Sepsis

Sepsis may be the cause of PH, and therefore blood cultures should be taken and appropriate antibiotics commenced.

Other therapies

These have with very limited evidence base but are detailed below. It may be appropriate to consider use of these therapies following discussion with a tertiary centre neonatologist when other therapies have not been successful.

- **Adrenaline**
The theoretical method of action is in constricting arterioles and reducing haemorrhage. There is a longitudinal study⁸ using endotracheal adrenaline. There was a statistically significant improvement in survival in the group given adrenaline, but they were compared to historical controls and the treatment group included just 5 infants. 1:10,000 adrenaline of 0.3-1ml/kg was given via catheter advanced through the endotracheal tube (i.e. like surfactant). A further retrospective study published in 2013⁹ gave 0.5ml of adrenaline (1 in 10,000) with 1ml of air using a 5ml syringe through an oral gastric tube. The authors gave the adrenaline after every suction and tried to create a 'force injection'. Suction was only used if there was dyspnea, hypercapnia or hypoxemia. In this study, it was felt that the adrenaline 'spraying' had an affect by the third to fifth dose. This study was completed on 18 VLBW neonates with severe pulmonary haemorrhage.
- **Hemocoagulase**
One study¹⁰ has been published with 28 infants treated with hemocoagulase. This demonstrated a significant reduction in mortality, however this drug is not currently available in the UK. There have been no RCTs looking at the effectiveness of this drug.
- **Cocaine**
Using a 4% cocaine spray (as used in some ENT departments) to promote vasoconstriction has been used in 1 study¹¹ however there is some concern regarding the use of cocaine in newborns and in addition it can be difficult to source.
- **Activated recombinant factor VII (rFVIIa)**
This is used in patients with severe haemophilia A and B who are bleeding. It has been used to treat severe PH which is refractory to conventional ventilator management in VLBW neonates. There have been case studies reported¹² describing two babies in which it was successful in controlling bleeding. There has also been a retrospective cohort study¹³ which comprised 18 infants (16 of which were premature) including 5 with pulmonary haemorrhage. Haemostasis was achieved in all infants with PH after 1-3 doses of 90 micrograms/kg. In the cohort, there was a baby diagnosed with a non-occlusive aortic thrombus on ultrasound (had also had a UAC in-situ). In adults, high dose rFVIIa has been associated with cerebral venous thrombosis, although there has not been a case reported in newborns.

6. Audit criteria

None identified

7. References

1. Antecedents of Clinically Significant Pulmonary Haemorrhage among Newborn Infants. Berger T et al. *Journal of Perinatology* 2000 5, 296.
2. Prevention and 18 month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the Trial of Indomethacin prophylaxis in Preterms. Alfaleh K et al. *Pediatrics* 2008; 121 e 233.
3. Neonatal Pulmonary Haemorrhage. Riad Abou Zahr, Ahmad Ashfaq, Mary Marron-Corwin. *Neoreviews*. Vol. 13 No.5 May 2012
4. Ductal Shunting, high pulmonary blood flow and pulmonary haemorrhage. Kluckow *Journal of Pediatrics* 136 (1) 68.
5. Pulmonary Hemorrhage in very low-birthweight infants: risk factors and management. Chen Y et al. *Pediatrics international* 2012.
6. High-Frequency Ventilation in the Management of Very-Low-Birth-Weight Infants with Pulmonary Hemorrhage. Turki M. AlKharfy. *Amer J Perinatol* 2004; 21(1): 19-26
7. Surfactant for pulmonary haemorrhage in neonates (review). Aziz a et al. *Cochrane database of systematic reviews*. 2012 Issue 7.
8. Pulmonary Hemorrhage in very low-birthweight infants: risk factors and management. Chen Y et al. *Pediatrics international* 2012.
9. Short- term Outcome of Pulmonary Haemorrhage in Very-Low-Birth-Weight Preterm Infants. Ting-An Yen, Ching-Chia Wang, Wu-Shiun Hsieh, Hung-Chieh Chou, Chen-Yi Chen, Po-Nien Tsao. *Pediatrics and Neonatology*. October 2013. Volume 54, Issue 5, Pages 330-334.
10. Role of Hemocoagulase in Pulmonary Hemorrhage in Preterm Infants: A Systematic Review. Abhay Lodha & Majeeda Kamaluddeen & Albert Akierman & Harish Amin. *Indian J Pediatr* (July 2011) 78(7):838–844.
11. Pulmonary hemorrhage in neonates of early and late gestation. Bhandari V, Gagnon C, Rosenkrantz T, Hussain NJ *Perinat Med*. 1999;27(5):369-75.
12. Treatment of Severe Pulmonary Hemorrhage With Activated Recombinant Factor VII (rFVIIa) in Very Low Birth Weight Infants. Nicholas Olomu, Roshni Kulkarni, Marilyn Manco-Johnson. December 2002, Volume 22, Number 8, Pages 672-674.
13. Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants. Chi N Dang, Lakshmi I Katakam, P Brian Smith, C Michael Cotten, Ronald N Goldberg, Nicole Chandler, Courtney D Thornburg, and Margarita Bidegain. *J Perinatol*. 2011 Mar; 31(3): 188–192.

